Randomized Phase III Trial Evaluating the Importance of Nephrectomy in Patients Presenting With Metastatic Renal Cell Carcinoma Treated With Sunitinib
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 10 Nov 2017
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms CARMENA
- 06 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 12 Nov 2015 Planned End Date changed from 1 Feb 2018 to 1 Feb 2020 as reported by ClinicalTrials.gov record.
- 12 Nov 2015 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2019 as reported by ClinicalTrials.gov record.